Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion is currently developing Ravicti™ (glycerol phenylbutyrate), formerly known as HPN-100, for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). Hyperion acquired the worldwide rights to Ravicti from Ucyclyd Pharma, Inc, a wholly owned subsidiary of Medicis Pharmaceutical Corporation in March 2012. Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price, Ucyclyd’s worldwide rights to BUPHENYL® and, subject to certain conditions, AMMONUL®. Hyperion is led by a seasoned executive team with extensive experience developing and commercializing specialty pharmaceutical products.
Looking for a particular Hyperion Therapeutics, Inc employee's phone or email?
Hyperion Therapeutics, Inc Questions
The Hyperion Therapeutics, Inc annual revenue was $113.6 million in 2026.
Marvin Garovoy is the SVP Clinical Development of Hyperion Therapeutics, Inc.
5 people are employed at Hyperion Therapeutics, Inc.
Hyperion Therapeutics, Inc is based in Brisbane, California.
The NAICS codes for Hyperion Therapeutics, Inc are [32, 3254, 325, 32541, 325412].
The SIC codes for Hyperion Therapeutics, Inc are [283, 28].
Top Hyperion Therapeutics, Inc Employees
-
Marvin Garovoy
SVP Clinical Development at Hyperion Therapeutics, Inc
South San Francisco, CA, US11 -
Cheryl Swanson
Senior Contracts Manager at Hyperion Therapeutics, Inc
San Francisco, CA, US14 -
Kevin P.
Network Systems Administrator at Hyperion Therapeutics, Inc
California, United States1
Related Companies
